Optimizing Outpatient Care: Clinical Strategies for Managing Hepatic Encephalopathy in Primary Practice : Episode 7
Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.
EP: 1.Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families
EP: 2.Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing
EP: 3.HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading
EP: 4.Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management
EP: 5.Preventing Cirrhosis Progression: Gut-Liver Axis, Circulation, Inflammation
EP: 6.Hepatic Encephalopathy: Exploring Alterations in Microbiota Caused by Liver Disease
Now Viewing
EP: 7.Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
EP: 8.AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety
EP: 9.Overview of Outpatient Strategies for Optimizing Patient Outcomes in HE
EP: 10.Managing Adverse Effects in HE Treatment
EP: 11.Practical Tips for the Primary Care Clinician Treating HE
EP: 12.Refractory Encephalopathy, Multivitamins and Closing Thoughts
- Which agents do we have to target abnormalities in gut-liver axis to prevent and treat HE? (lactulose or lactitol, rifaximin) Sanchez-Delgado et al 2016
- What is the mechanism of action of these therapies?
- What is their tolerability and their side effect profile?
Recent Videos
Related Content
